For: | Petagine L, Zariwala MG, Patel VB. Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments. World J Gastroenterol 2023; 29(32): 4831-4850 [PMID: PMC10494768 DOI: 10.3748/wjg.v29.i32.4831] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i32/4831.htm |
Number | Citing Articles |
1 |
Ziwei Guo, Qinjuan Wu, Pengfei Xie, Jiuchong Wang, Wenliang Lv. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1336493
|
2 |
Mohammadreza Gholamrezapour, Raziyeh Taghizadeh Ghavamabadi, Mohammad Mohsen Taghavi, Samereh Dehghani Soltani, Ahmad Shabanizadeh, Reza Vazirinejad, Zahra Taghipour. Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells. Journal of Molecular Histology 2025; 56(1) doi: 10.1007/s10735-024-10313-2
|
3 |
Ahmed M. Samy, Mohamed A. Kandeil, Dina Sabry, A.A. Abdel-Ghany, Mohamed O. Mahmoud. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences. Heliyon 2024; 10(9): e30387 doi: 10.1016/j.heliyon.2024.e30387
|
4 |
Lakshmi Arivazhagan, Sofie Delbare, Robin A. Wilson, Michaele B. Manigrasso, Boyan Zhou, Henry H. Ruiz, Kaamashri Mangar, Ryoko Higa, Emily Brown, Huilin Li, Michael J. Garabedian, Ravichandran Ramasamy, Kathryn J. Moore, Edward A. Fisher, Neil D. Theise, Ann Marie Schmidt. Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet. JHEP Reports 2025; 7(2): 101222 doi: 10.1016/j.jhepr.2024.101222
|
5 |
Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander. Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines 2025; 13(1): 80 doi: 10.3390/biomedicines13010080
|
6 |
U. Arshad, J.E.P. Santos. Graduate Student Literature Review: Exploring choline's important roles as a nutrient for transition dairy cows. Journal of Dairy Science 2024; 107(7): 4357 doi: 10.3168/jds.2023-24050
|
7 |
Shao-Hong Tao, Yu-Qing Lei, Yi-Mei Tan, Yu-Bo Yang, Wei-Ning Xie. Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1476419
|
8 |
Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara, Masafumi Ono, Takashi Himoto, Tsutomu Masaki. MicroRNAs and Nonalcoholic Steatohepatitis: A Review. International Journal of Molecular Sciences 2023; 24(19): 14482 doi: 10.3390/ijms241914482
|
9 |
Sainan Tang, Shanshan Wu, Wenzhe Zhang, Lili Ma, Li Zuo, Hua Wang. Immunology and treatments of fatty liver disease. Archives of Toxicology 2025; 99(1): 127 doi: 10.1007/s00204-024-03920-1
|
10 |
Ming-yu He, Xin-jie Du, Yi-ming Liu. Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-03612-9
|
11 |
Isabella D. Cooper, Yvoni Kyriakidou, Kurtis Edwards, Lucy Petagine, Thomas N. Seyfried, Tomas Duraj, Adrian Soto-Mota, Andrew Scarborough, Sandra L. Jacome, Kenneth Brookler, Valentina Borgognoni, Vanusa Novaes, Rima Al-Faour, Bradley T. Elliott. Ketosis Suppression and Ageing (KetoSAge): The Effects of Suppressing Ketosis in Long Term Keto-Adapted Non-Athletic Females. International Journal of Molecular Sciences 2023; 24(21): 15621 doi: 10.3390/ijms242115621
|
12 |
Sazid Hasan, Aida Brankovic, Md Abdul Awal, Sasan Ahdi Rezaeieh, Shelley E. Keating, Amin M. Abbosh, Ali Zamani. HepNet: Deep Neural Network for Classification of Early-Stage Hepatic Steatosis Using Microwave Signals. IEEE Journal of Biomedical and Health Informatics 2025; 29(1): 142 doi: 10.1109/JBHI.2024.3489626
|
13 |
Grigorios Papadopoulos, Eirini Giannousi, Aikaterini P. Avdi, Rallia-Iliana Velliou, Polyxeni Nikolakopoulou, Antonios Chatzigeorgiou. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1343806
|
14 |
Karolina Dereń, Joanna Kapusta-Duch, Teresa Leszczyńska, Barbara Borczak, Marta Kotuła. Pro-Health Potential of Selected Uncommon Oilseed Plants. Applied Sciences 2024; 14(19): 8843 doi: 10.3390/app14198843
|
15 |
Rhys W. Niedecker, Joseph A. Delaney, Margaret F. Doyle, Andrew D. Sparks, Colleen M. Sitlani, Petra Buzkova, Irfan Zeb, Russell P. Tracy, Bruce M. Psaty, Matthew J. Budoff, Nels C. Olson. Investigating peripheral blood monocyte and T-cell subsets as non-invasive biomarkers for asymptomatic hepatic steatosis: results from the Multi-Ethnic Study of Atherosclerosis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1243526
|
16 |
Zhenguo Luo, Shu Yan, Yu Chao, Ming Shen. Unveiling the mitophagy puzzle in non-alcoholic fatty liver disease (NAFLD): Six hub genes for early diagnosis and immune modulatory roles. Heliyon 2024; 10(7): e28935 doi: 10.1016/j.heliyon.2024.e28935
|
17 |
Isabella D. Cooper, Yvoni Kyriakidou, Lucy Petagine, Kurtis Edwards, Adrian Soto-Mota, Kenneth Brookler, Bradley T. Elliott. Ketosis Suppression and Ageing (KetoSAge) Part 2: The Effect of Suppressing Ketosis on Biomarkers Associated with Ageing, HOMA-IR, Leptin, Osteocalcin, and GLP-1, in Healthy Females. Biomedicines 2024; 12(7): 1553 doi: 10.3390/biomedicines12071553
|
18 |
ChongLi Xu, Fengyang Fu, Yuhan She, ChongBo Xu. NPC1L1 Plays a Novel Role in Nonalcoholic Fatty Liver Disease. ACS Omega 2023; 8(51): 48586 doi: 10.1021/acsomega.3c07337
|
19 |
Winston T. Stauffer, Asha Z. Goodman, Philippe A. Gallay. Cyclophilin inhibition as a strategy for the treatment of human disease. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1417945
|